-
The release of heavy documents, the Internet medical industry may welcome a major reshuffle
Time of Update: 2021-11-14
The proposal of the "Draft of Opinions" has just raised the barriers to entry for the industry, which will benefit the development of Internet diagnosis and treatment platforms that provide technical services, and will also bring more challenges to platforms that focus on medical e-commerce .
-
21 batches of medicines in Yunnan Province were found to be unqualified, and Chinese herbal medicines accounted for the majority
Time of Update: 2021-11-14
Subsequently, in May of the same year, the State Food and Drug Administration held a video and telephone conference, requesting drug regulatory authorities at all levels to implement territorial regulatory responsibilities in accordance with the "four strictest" requirements, carefully inspect the production and operation units of traditional Chinese medicine decoction pieces and preparations, and resolutely investigate and punish violations of the law.
-
Announcement of the State Food and Drug Administration on the conversion of aloe pearl capsule prescription drugs to over-the-counter drugs (No. 115 of 2021)
Time of Update: 2021-11-14
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
Variety of non-prescription drug instructions template State Drug Administration September 23, 2021 State Drug Administration Announcement No.
-
The State Food and Drug Administration issued two supplementary inspections on the inspection items of permanganate in ginseng and American ginseng medicinal materials and the inspection items of bovine origin in Ejiao Yishou oral liquid
Time of Update: 2021-11-14
According to the relevant provisions of the "Drug Administration Law of the People's Republic of China" and its implementation regulations, the "Supplementary Inspection Method for Permanganate Inspection Items in Ginseng and American Ginseng Medicinal Materials" and "Supplementary Inspection Method for Cowhide Source Components Inspection Items in Ejiao Yishou Oral Liquid" have been approved by the state Approved by the Drug Administration, it is hereby released .
-
Johnson & Johnson, U.S., etc. are all developing the first FcRn-targeted new drug. When will it arrive?
Time of Update: 2021-11-14
In addition, another important research direction in this field is to develop drugs to inhibit the binding of endogenous FcRn and IgG, thereby treating autoimmune diseases driven by autoantibody .
-
The place will carry out the purchase of low-value consumables with a quantity, and the product decline may be very substantial
Time of Update: 2021-11-14
The notice pointed out that after the implementation of the Internet, in addition to first aid and other clinical needs, low-value medical consumables and test reagents used by public medical and health institutions in the city must be purchased on the procurement platform.
-
Announcement of the General Administration of Customs of the State Food and Drug Administration on the addition of Changchun Air Port as a port for drug import (No. 79 of 2021)
Time of Update: 2021-11-14
2. Adding Jilin Provincial Drug Administration as the port drug supervision and management department, which will undertake the specific work of the record of drug imports at Changchun Airport .
Since the date of this announcement, Jilin Provincial Institute of Drug Inspection has begun to undertake the inspection of drugs at Changchun Airport .
-
The National Medical Insurance Bureau issued the national procurement renewal document: no "only bargaining, no quantity"!
Time of Update: 2021-11-14
In addition, in response to previous penalties for winning bids for failing to supply the agreed procurement volume in accordance with the agreement, the "Notice" also made provisions on "strengthening credit and performance evaluation", "improving supporting policies", and "strengthening performance supervision".
-
National Health Commission: Promote the integration and sharing of resources to implement the functional positioning of county hospitals in the hierarchical diagnosis and treatment system
Time of Update: 2021-11-14
Original title: National Health Commission: Promote the integration and sharing of resources to implement the functional positioning of county hospitals in the hierarchical diagnosis and treatment system The General Office of the National Health Commission issued the "Thousand Counties Project" County Hospital Comprehensive Capacity Improvement Work Plan (2021-2025), striving to achieve the level of tertiary hospital medical service capacity in at least 1,000 county hospitals across the country by 2025.
-
Announcement of the State Food and Drug Administration on the conversion of compound Banlangen Granules into over-the-counter drugs (No. 58 of 2021)
Time of Update: 2021-11-14
The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together .
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
-
TOP10 failed clinical studies in October 2021
Time of Update: 2021-11-14
Phase III study of Canakinumab in the treatment of non-small cell lung cancerNovartis announced on October 25 that the IL-1β inhibitor Canakinumab (canakinumab, ACZ885) combined with pembrolizumab plus platinum dual-drug chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) The phase III clinical study (CANOPY-1) failed to achieve the primary endpoints of improving overall survival (OS) and progression-free survival (PFS) .
-
Shandong: 115 drugs have been transferred out of medical insurance today!
Time of Update: 2021-11-14
Recently, Shandong Province Public Resource Exchange Center issued the "Notice on the province basic medical insurance, industrial injury insurance and maternity insurance drug list additions drugs in 2021 transferred out of work" .
-
Announcement of the State Food and Drug Administration on the issuance of two supplementary inspection methods for the rosin acid check item in Xiaozhong tablets and the check item of rhubarb glycosides in compound gentian sodium bicarbonate tablets (
Time of Update: 2021-11-14
Supplementary inspection method for rhubarb glycosides inspection items in compound gentian sodium bicarbonate tablets National Medical Products Administration October 12, 2021 National Medical Products Administration 2021 Announcement No.
-
2020 Chinese Hospitals and Chinese Medical Colleges Science and Technology Values (STEM) released
Time of Update: 2021-11-14
( Photo courtesy of the Chinese Academy of Medical Sciences) The picture shows Wang Chen interpreting and releasing the 2020 STEM values for Chinese hospitals/medical colleges .
-
Novartis' potential "first-in-class" complement inhibitor reaches phase 2 clinical endpoint
Time of Update: 2021-11-14
Today, Novartis announced that its potential "first-in-class" oral factor B inhibitor iptacopan (LNP023) has reached its primary clinical endpoint in a phase 2 clinical trial for the treatment of patients with C3 glomerulopathy (C3G).
-
Merck's "Cetuximab" New Indication Application for Listing
Time of Update: 2021-11-14
At present, cetuximab has been approved for marketing in more than 100 countries around the world, mainly for the treatment of colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN) .
-
[FDA] The first C5aR inhibitor comes out!
Time of Update: 2021-11-14
S. FDA announced the approval of ChemoCentryx's oral selective complement 5a receptor (C5aR) inhibitor Tavneos (avacopan) to be marketed, combined with standard therapies to treat severely active antineutrophil cytoplasmic autoantibodies (ANCA) ) Related vasculitis, including granulomatous polyangiitis (GPA) and microscopic polyangiitis (MPA) .
-
ADC drugs enter the hot spot of industry attention, and domestic research and development is booming
Time of Update: 2021-11-14
7 billion yuan, invest in the construction of the company’s Hangzhou biopharmaceutical project, engage in the research and development of anti-tumor ADC drugs, and set up other Subsidiaries and other industries .
-
The peptide drug market in my country has further expanded, and these companies are worth recommending
Time of Update: 2021-11-14
As a domestic peptide drug company, Sino Bio has always established its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials .
-
Asia Pacific Pharmaceuticals Mosapride Citrate Granules Obtained Drug Registration Certificate
Time of Update: 2021-11-14
On November 4, Asia-Pacific Pharmaceuticals issued an announcement stating that the company had received the "Drug Registration Certificate" for the chemical mosapride citrate granules approved and issued by the National Medical Products Administration .
No other company has obtained the registration certificate of the drug granules.